I do remember reading an interview transcript from one of the directors a while back that said they had planned the Phase II to meet the standards of a phase III. You better believe that positive results from the phase III study in addition if the phase II/III was accepted as a phase III trial, I could see the stock easily doubling from here. It would make the BO even more attractive to suitors.
With phase III trial results coming out for CIC and Phase II results coming for IBS and the market value of such a drug, I would have to think that a buyout is a strong possibility. With Phase II for IBS already showing positive results in over 900 patients, which is a huge sample size for that phase, it provides a large body of work that supports the efficacy and safety of the drug. A single positive phase III should only confirm that.
Is it possible that companies will want to wait for Positive results from SP-333 for UC and OIC before jumping into the game? I foresee this company getting much more expensive as a buyout the longer this goes on, especially since much of the groundwork has been laid by Ironwood.
And that my friends, is why you can't time the market. Have to admit though, the roller coaster can get kind of stressful at times. Have to keep reminding myself to look at the big picture. Granted, there will be more days with big swings, but I feel very good about the direction.
Yes! As we orchestrate the offense to throw over the heads and burn deep the Richard Sherman loud mouths, aka Stillondgo, and get the victory. :-)
Though bioequivalence was shown, is there evidence that with the dissolvable film that the onset of an erection was much quicker? I would think that would be the biggest selling point is that the medication acts quicker.
Just curious as Abstral is a sublingual pill of Fentanyl, which of course is not as strong as Zalviso. Our ACRX1, being strictly provided in controlled settings, should be approved, I would think. Would really be surprised if it isn't with the feedback from the doctors and nurses to go along with the patients. With the devices that the company has created to help monitor the use and potential abuse, I feel like they are trying to address the potential concerns the FDA would have.
lol.....looking at your history of posting, you offer very little to a board anyways since all of your postings revolve around people bashing a stock. Carry on. lol
I'm sorry, you are comparing Zalviso with Provenge, a cancer drug, which I believe is north of $80,000 per treatment? What? What you are you talking about?
Results showed consistent and effective results for Ventrus drug. Placebo did not! Thus, it is not inferior and still showed good results, just not significantly more than Placebo. As there is only one approved product and several others being used that arent FDA approved, this provides another option. Plus, aren't the costs of Ven 307 much cheaper?
Kami, it would be hard to imagine the trial not reaching its endpoints, especially with the first trial showing successful results and the fact that the proof is already there being that it is already used in a compounded (non-FDA approved) formulation. I am more concerned with issues such as manufacturing, packaging and labeling information that the FDA may not agree with when it comes time for approval.
I would agree that something to that effect is taking place. I was in Santarus for years and despite a great outlook, would continue to have serious downtrends. As we know, the company got bought out after it had lost over 20% of its value.
I also agree that with the end of the year selling and people taking profits on the latest run are also factors. Shaking my head that I didn't sell higher and lock my gains in. Things look very good, imo, though.
My God, first of all, people in supposed pain are going to put a pill in their hospital gown? Seriously? This argument makes little sense and could be applied to any drug not IV related. Maybe the nurse should have checked to see that the woman actually swallowed the percoset pills and didn't just put them under her tongue and pretend to swallow them, also. Otherwise, maybe it will end up in her pocket.
Curious as to why pain relief was 30 minutes in the study as to ACRX01 results that show pain relief is quicker than IV morphine. Was it a lower dose? Need to go back, obviously, and read the study, but was hoping you could help me out here. Thanks.
What is the difference? Both are being administered in supervised settings one in hospitals by the patient and one outside by an EMT. I realize 04 is for military purposes, also. Is it the mechanism and device in which the medication is taken or why do we need two different trials for the drug. We have already proven the effectiveness of the drug. It makes no sense to me. Why couldn't the drug be administered by EMT's and military personnel Upon the drugs approval?
Pretty interesting stuff. The BO negotiations actually started around October 11th. For all of us who were griping about $32, the original buyout was $30 plus a $3 contingent value for Ruconest. Salix then decided to no include Ruconest in the bid.
Couldn't find any of their quarterly updates since they are not a publicly held company. Are they a realistic suitor to buy out ACRX?
Also, though a buyout could happen before approval, are we looking at updates for phase II trials as future catalysts? Just wanting more thoughts as to whether this will trade like DRTX for a while and swing up and down.
No, I didn't. That was all pretty neat though how all those things were documented. I went back and checked the price range over that time and there wasn't much difference. I think we went up a $1.50 or so, with the big daily swings. At least I was able to take a huge chunk of that and put in ACRX. Hope it pays off as well as SNTS and TSRX has.
Great response, tough guy. I'm not a short, moron, and simply asked a question. I currently have quite a lot invested in ACRX. Looking at their site and can't seem to find where their financials are. Simply providing some assistance or some guidance in the area without acting like a complete tool would be an option, also. All I am trying to do is find out more about the company.